Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-arm, multicenter, phase II trial for comparing Camrelizumab (SHR-1210) combined with induction chemotherapy and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Next Previous
X
Search
Trial Profile

A prospective, single-arm, multicenter, phase II trial for comparing Camrelizumab (SHR-1210) combined with induction chemotherapy and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Camrelizumab (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2023 Preliminary results (n=49) assessing safety and efficacy of Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top